Diabetic Kidney Disease Collaborative (DKD-C): Addressing the Urgent and Unmet Needs of People with DKD
- Informational Posters - II
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- No subcategory defined
- Tuttle, Katherine R., University of Washington School of Medicine, Seattle, Washington, United States
- Argyropoulos, Christos, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
- Brosius, Frank C., The University of Arizona College of Medicine Tucson, Tucson, Arizona, United States
- Cherney, David, Toronto General Hospital, Toronto, Ontario, Canada
- Gee, Patrick O., iAdvocate, North Chesterfield, Virginia, United States
- Harris, Raymond C., Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Kliger, Alan S., Yale School of Medicine, New Haven, Connecticut, United States
- Mottl, Amy K., The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
- Nachman, Patrick H., University of Minnesota Twin Cities School of Medicine, Minneapolis, Minnesota, United States
- Quaggin, Susan E., Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Group or Team Name
- Diabetic Kidney Disease Collaborative
Background: The American Society of Nephrology Diabetic Kidney Disease Collaborative (DKD-C) was formed to address the urgent and unmet needs of people with DKD.
Methods: The DKD-C convened a series of conferences that included patients; providers from primary care, cardiology, endocrinology, and nephrology; and representatives of industry and the Food and Drug Administration as key stakeholders who crafted management priorities for DKD. The DKD-C has published a series of high-impact papers emanating from these conferences. An educational module focused on the patient journey for “Management of Chronic Kidney Disease in People with Diabetes” was assembled by national leaders in the field and is freely available online. This resource is being adapted into a patient-focused tool authored by and for the patient community. The DKD-C is partnering with the Veterans Administration and another large United States healthcare system to analyze the cost-effectiveness of SGLT2 inhibitor treatment for DKD and to determine whether such guideline-directed medical therapies have a positive impact on work productivity, quality of life, job satisfaction, and total medical costs.
Results: In less than five years, the DKD-C has engaged healthcare and patient communities to create resources for multidisciplinary practitioners caring for patients with DKD. Next steps include a valuable patient-focused educational tool, available online for patients and their care partners to understand more about their condition, how to communicate better with their care providers, and what optimal treatment options are available. The SGLT2 cost-effectiveness analysis will demonstrate the clinical and economic impact of adopting guideline directed medical therapy for patients, providers, health systems, and payers.
Conclusions: Access to care and implementation of breakthrough therapies for DKD can save millions of lives by preventing kidney failure, cardiovascular events, and death. The DKD-C remains focused on disseminating knowledge and promoting equitable use of lifesaving treatments and prevention strategies to improve the health of people and communities worldwide.
- American Society of Nephrology